Two healthcare multibaggers below $5 to keep a close eye on

Source: Josep Suria, Shutterstock 

Healthcare, one of the biggest and most convoluted sectors in the trade market, is made up of a wide assortment of companies dealing with pharma, medical, fitness and other healthcare facilities and products. While many of the companies sell drugs and medical devices, some are involved in insurance and researches.

Investors are keeping a close eye on entire healthcare segment because it is one sector which not only survived the economic meltdown but also flourished during the coronavirus pandemic, and trended the most among all other sections on the ASX, thanks to the demand for medical and pharma-related products and services.

Following are the stocks valued under $5 per share which gained the most in the past one year, and are under watch:

Telix Pharmaceuticals Limited (ASX:TLX)

Boasting of a mission to help patients with cancer, making them live longer, and improve their lives, Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine. Telix, at present, mainly focuses on unmet requirements in cancer care, specifically in the cancer of prostate, kidney and brain.

On 22 February, the Company made a significant announcement. It informed that its subsidiary Telix Pharmaceuticals Japan KK has hit a jackpot as it got clearance on Clinical Trial Notification by the Japanese Pharmaceuticals and Medical Devices Agency (PDMA) to commence Phase 1 trial of TLX591-CDx in Japan itself. This trial will be done in alliance with Kanazawa University.  TLX591-CDx is a prostate cancer imaging product.

Image Source: Pexels

The quarter also witnessed the company receiving National Authorisation from Czech Republic for its TLX591-CDx product. The national authorisation enables Czech physicians to use TLX591-CDx (specific to Telix’s prostate cancer imaging product) under a Specific Therapeutic Programme (STP).

On 10 February 2021, TLX inked a research cooperation agreement with Germany based Heidelberg University Hospital to develop next-gen theranostic radiopharmaceuticals for urologic oncology.

Meanwhile, the Company stock TLX is priced at AU$3.83 with market capitalisation at AU$1.10 billion and has gained 181.72% in the past one year.

Anteotech LTD (ASX:ADO)

Anteotech has shown an unprecedented growth of 880.90% in the past one year and has been in news for various developments every now and then.

A Company engaged in developing and branding medical and pharma goods under the healthcare sector, AnteoTech currently has two ways to contribute to deliver global solutions – point of care diagnosis of a disease to speed up delivery of medical intervention and enabling efficient use of electricity via the lithium-ion battery.

Image Source: Pexels

On 29 January 2021, the Company shared its key activities for the quarter ended 31 December 2020. As per the report, the busy quarter witnessed Life Sciences team getting ahead with the advancement of authenticating and commercialising the Company’s COVID-19 ART. To add to this, ADO’s energy team showed substantial development on the Cross-Linker Additive and the expansion of Silicon Composite anodes.

The quarter saw COVID-19 test development going through important breakthrough points. To add to this, representatives are appointed in Europe to work alongside the Company to finalise the distribution arrangement during the coming months.

The report informed that the State government of Queensland had bestowed an up to $1.4 million grant to the Company. This was done in order to empower ADO’s market differentiation and carve a path for raising revenues.

On 3 February 2021, the Brisbane-based nanotechnology Company shared that its customer Ellume had struck a deal with the US Department of Defense for its Emergency Use Authorization (EUA) COVID-19 at home test. The Ellume COVID-19 home test, incorporating AnteoBind, is the first non-prescription over-the-counter self-test which has been authorised by the US FDA for emergency use.

Meanwhile, the stock closed the week’s session at AU$0.235 per share, down 4.082% with market capitalisation at AU$458.18 million.


The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK